A nonsynonymous TNFRSF11A variation increases NFκB activity and the severity of Paget's disease

Journal of Bone and Mineral Research

Volumn 27, Issue 2, 2012, Pages 443-452

  Gianfrancesco, Fernando ^a   Rendina, Domenico ^b   Di Stefano, Marco ^c   Mingione, Alessandra ^a   Esposito, Teresa ^a   Merlotti, Daniela ^d   Gallone, Salvatore ^e   Magliocca, Sara ^a   Goode, Alice ^f   Formicola, Daniela ^a   Morello, Giovanna ^a   Layfield, Robert ^f   Frattini, Annalisa ^g   De Filippo, Gianpaolo ^b   Nuti, Ranuccio ^d   Searle, Mark ^f   Strazzullo, Pasquale ^b   Isaia, Giancarlo ^c   Mossetti, Giuseppe ^b   Gennari, Luigi ^d  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

Author keywords

GENE GENE INTERACTION; NF B ACTIVITY; SEVERITY OF PAGET'S DISEASE OF BONE; TNFRSF11A GENE; V192A

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ALLELE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC TRANSFECTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; ITALY; MAJOR CLINICAL STUDY; PAGET BONE DISEASE; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84856190866     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.542     Document Type: Article

References (47)

1. Roodman GD, Windle JJ,. Paget disease of bone. J Clin Invest. 2005; 115: 200-8. (Pubitemid 40385458)
2. Ralston SH, Langston AL, Reid IR,. Pathogenesis and management of Paget's disease of bone. Lancet. 2008; 72: 155-63. (Pubitemid 351952259)
3. Montagu MF,. Paget's disease (osteitis deformans) and hereditary. Am J Hum Genet. 1949; 1: 94-5.
4. Siris ES, Ottman R, Flaster E, Kelsey JL,. Familial aggregation of Paget's disease of bone. J Bone Miner Res. 1991; 6: 495-500.
5. Siris ES,. Epidemiological aspects of Paget's disease: family history and relationship to other medical conditions. Semin Arthritis Rheum. 1994; 23: 222-5. (Pubitemid 24077088)
6. Morales-Piga AA, Rey-Rey JS, Corres-González J, García-Sagredo JM, López-Abente G,. Frequency and characteristics of familial aggregation of Paget's disease of bone. J Bone Miner Res. 1995; 10: 663-70.
7. Ralston SH,. Pathogenesis of Paget's disease of bone. Bone. 2008; 43: 819-25.
8. Laurin N, Brown JP, Morissette J, Raymond V,. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet. 2002; 70: 1582-8. (Pubitemid 34533906)
9. Hocking LJ, Lucas GJ, Daroszewska A, Mangion J, Olavesen M, Cundy T, Nicholson GC, Ward L, Bennett ST, Wuyts W, Van Hul W, Ralston SH,. Domain specific mutations in Sequestosome 1 (SQSTM1) cause familial and sporadic Paget's disease. Hum Mol Genet. 2002; 11: 2735-9. (Pubitemid 35214900)
10. Layfield R,. The molecular pathogenesis of Paget disease of bone. Expert Rev Mol Med. 2007; 9: 1-13. (Pubitemid 47506363)
11. Goode A, Layfield R,. Recent advances in understanding the molecular basis of Paget disease of bone. J Clin Pathol. 2010; 63: 199-203.
12. Kurihara N, Hiruma Y, Zhou H, Subler MA, Dempster DW, Singer FR, Reddy SV, Gruber HE, Windle JJ, Roodman GD,. Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. J Clin Invest. 2007; 117: 133-42. (Pubitemid 46048460)
13. Hiruma Y, Kurihara N, Subler MA, Zhou H, Boykin CS, Zhang H, Ishizuka S, Dempster DW, Roodman GD, Windle JJ,. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet. 2008; 17: 3708-19.
14. Reddy SV,. Etiologic factors in Paget's disease of bone. Cell Mol Life Sci. 2006; 63: 391-8.
15. Rea SL, Walsh JP, Ward L, Magno AL, Ward BK, Shaw B, Layfield R, Kent GN, Xu J, Ratajczak T,. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-kappaB signaling without loss of ubiquitin binding. J Bone Miner Res. 2009; 24: 1216-23.
16. Gennari L, Gianfrancesco F, Di Stefano M, Rendina D, Merlotti D, Esposito T, Gallone S, Fusco P, Rainero I, Fenoglio P, Mancini M, Martini G, Bergui S, De Filippo G, Isaia G, Strazzullo P, Nuti R, Mossetti G,. SQSTM1 gene analysis and gene-environment interaction in Paget's disease of bone. J Bone Miner Res. 2010; 25: 1375-84.
17. Leach RJ, Singer FR, Ench Y, Wisdom JH, Pina DS, Johnson-Pais TL,. Clinical and cellular phenotypes associated with sequestosome 1 (SQSTM1) mutations. J Bone Miner Res. 2006; 21: 45-50.
18. Bolland MJ, Tong PC, Naot D, Callon KE, Wattie DJ, Gamble GD, Cundy T,. Delayed development of Paget's disease in offspring inheriting SQSTM1 mutations. J Bone Miner Res. 2007; 22: 411-5. (Pubitemid 46797124)
19. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, van Hul W, Whyte MP, Nakatsuka K, Hovy L, Anderson DM,. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000; 24: 45-8. (Pubitemid 30041418)
20. Sparks AB, Peterson SN, Bell C, Loftus BJ, Hocking L, Cahill DP, Frassica FJ, Streeten EA, Levine MA, Fraser CM, Adams MD, Broder S, Venter JC, Kinzler KW, Vogelstein B, Ralston SH,. Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. Calcif Tissue Int. 2001; 68: 151-5. (Pubitemid 32374475)
21. Whyte MP, Hughes AE,. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002; 17: 26-9. (Pubitemid 33150993)
22. Nakatsuka K, Nishizawa Y, Ralston SH,. Phenotypic characterization of early onset Paget's disease of bone caused by a 27-bp duplication in the TNFRSF11A gene. J Bone Miner Res. 2003; 18: 1381-5. (Pubitemid 41070792)
23. Marco-Mingot M, San-Millan JL, Wuyts W, Bachiller-Corral J, Van HW, Morales-Piga AA,. Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. Clin Genet. 2001; 60: 86-8. (Pubitemid 32677790)
24. Wuyts W, Van Wesenbeeck L, Morales-Piga A, Ralston S, Hocking L, Vanhoenacker F, Westhovens R, Verbruggen L, Anderson D, Hughes A, Van Hul W,. Evaluation of the role of RANK and OPG genes in Paget's disease of bone. Bone. 2001; 28: 104-7. (Pubitemid 32112068)
25. Chung PY, Beyens G, Riches PL, Van Wesenbeeck L, de Freitas F, Jennes K, Daroszewska A, Fransen E, Boonen S, Geusens P, Vanhoenacker F, Verbruggen L, Van Offel J, Goemaere S, Zmierczak HG, Westhovens R, Karperien M, Papapoulos S, Ralston SH, Devogelaer JP, Van Hul W,. Genetic variation in the TNFRSF11A gene encoding RANK is associated with susceptibility to Paget's disease of bone. J Bone Miner Res. 2010; 25: 2316-29.
26. Chung PY, Beyens G, Boonen S, Papapoulos S, Geusens P, Karperien M, Vanhoenacker F, Verbruggen L, Fransen E, Van Offel J, Goemaere S, Zmierczak HG, Westhovens R, Devogelaer JP, Van Hul W,. The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes. Hum Genet. 2010; 128: 615-26.
27. Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, del Pino Montes J, Gonzalez-Sarmiento R, di Stefano M, Tenesa A, Walsh JP, Ralston SH,. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat Genet. 2010; 42: 520-4.
28. Cavey JR, Ralston SH, Hocking LJ, Sheppard PW, Ciani B, Searle MS, Layfield R,. Loss of ubiquitin-binding associated with Paget's disease of bone p62 (SQSTM1) mutations. J Bone Miner Res. 2005; 20: 619-24. (Pubitemid 40393070)
29. Cavey JR, Ralston SH, Sheppard PW, Ciani B, Gallagher TR, Long JE, Searle MS, Layfield R,. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif Tissue Int. 2006; 78: 271-7. (Pubitemid 43725186)
30. Rea SL, Walsh JP, Ward L, Yip K, Ward BK, Kent GN, Steer JH, Xu J, Ratajczak T,. A novel mutation (K378X) in the sequestosome 1 gene associated with increased NF-kappaB signaling and Paget's disease of bone with a severe phenotype. J Bone Miner Res. 2006; 21: 1136-45. (Pubitemid 43962843)
31. Sebban-Benin H, Pescatore A, Fusco F, Pascuale V, Gautheron J, Yamaoka S, Moncla A, Ursini MV, Courtois G,. Identification of TRAF6-dependent NEMO polyubiquitination sites through analysis of a new NEMO mutation causing incontinentia pigmenti. Hum Mol Genet. 2007; 16: 2805-15. (Pubitemid 350048380)
32. Kearns AE, Khosla S, Kostenuik PJ,. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008; 29: 155-92. (Pubitemid 351519689)
33. Haslam SI, Van Hul W, Morales-Piga A, Balemans W, San-Millan JL, Nakatsuka K, Willems P, Haites NE, Ralston SH,. Paget's disease of bone: evidence for a susceptibility locus on chromosome 18q and for genetic heterogeneity. J Bone Miner Res. 1998; 13: 911-7. (Pubitemid 28265268)
34. Hocking L, Slee F, Haslam SI, Cundy T, Nicholson G, van Hul W, Ralston SH,. Familial Paget's disease of bone: patterns of inheritance and frequency of linkage to chromosome 18q. Bone. 2000; 26: 577-80. (Pubitemid 30301649)
35. Yip KH, Feng H, Pavlos NJ, Zheng MH, Xu J,. p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone. Am J Pathol. 2006; 169: 503-14. (Pubitemid 44156310)
36. Rendina D, Gennari L, De Filippo G, Merlotti D, de Campora E, Fazioli F, Scarano G, Nuti R, Strazzullo P, Mossetti G,. Evidence for increased clinical severity of familial and sporadic Paget's disease of bone in Campania, southern Italy. J Bone Miner Res. 2006; 21: 1828-35. (Pubitemid 44851557)
37. The Genetic Determinants of Paget's Disease (GDPD) Consortium, Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, Montes JD, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH, Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat Genet. 2011 May 29. [Epub ahead of print]
38. Kurihara N, Hiruma Y, Yamana K, Michou L, Rousseau C, Morissette J, Galson DL, Teramachi J, Zhou H, Dempster DW, Windle JJ, Brown JP, Roodman GD,. Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget's disease. Cell Metab. 2011; 13: 23-34.
39. Guerrini MM, Sobacchi C, Cassani B, Abinun M, Kilic SS, Pangrazio A, Moratto D, Mazzolari E, Clayton-Smith J, Orchard P, Coxon FP, Helfrich MH, Crockett JC, Mellis D, Vellodi A, Tezcan I, Notarangelo LD, Rogers MJ, Vezzoni P, Villa A, Frattini A,. Human osteoclast-poor osteopetrosis with hypogammaglobulinemia due to TNFRSF11A (RANK) mutations. Am J Hum Genet. 2008; 83: 64-76. (Pubitemid 351916706)
40. Marsters SA, Frutkin AD, Simpson NJ, Fendly BM, Ashkenazi A,. Identification of cysteine-rich domains of the type 1 tumor necrosis factor receptor involved in ligand binding. J Biol Chem. 1992; 267: 5747-50.
41. Naismith JH, Sprang SR,. Modularity in the TNF-receptor family. Trends Biochem Sci. 1998; 23: 74-9. (Pubitemid 28085231)
42. Liu C, Walter TS, Huang P, Zhang S, Zhu X, Wu Y, Wedderburn LR, Tang P, Owens RJ, Stuart DI, Ren J, Gao B,. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol. 2010; 184: 6910-9.
43. Richards JB, Kavvoura FK, Rivadeneira F, Styrkársdóttir U, Estrada K, Halldórsson BV, Hsu YH, Zillikens MC, Wilson SG, Mullin BH, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra BA, Pols HA, Sigurdsson G, Thorsteinsdottir U, Soranzo N, Williams FM, Zhou Y, Ralston SH, Thorleifsson G, van Duijn CM, Kiel DP, Stefansson K, Uitterlinden AG, Ioannidis JP,. Spector TD; Genetic Factors for Osteoporosis Consortium. Collaborative meta-analysis: associations of 150 candidate genes with osteoporosis and osteoporotic fracture. Ann Intern Med. 2009; 151: 528-37.
44. Rivadeneira F, Styrkársdottir U, Estrada K, Halldórsson BV, Hsu YH, Richards JB, Zillikens MC, Kavvoura FK, Amin N, Aulchenko YS, Cupples LA, Deloukas P, Demissie S, Grundberg E, Hofman A, Kong A, Karasik D, van Meurs JB, Oostra B, Pastinen T, Pols HA, Sigurdsson G, Soranzo N, Thorleifsson G, Thorsteinsdottir U, Williams FM, Wilson SG, Zhou Y, Ralston SH, van Duijn CM, Spector T, Kiel DP, Stefansson K, Ioannidis JP, Uitterlinden AG;, Genetic Factors for Osteoporosis (GEFOS) Consortium. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat Genet. 2009; 41: 1199-206.
45. Hsu YH, Niu T, Terwedow HA, Xu X, Feng Y, Li Z, Brain JD, Rosen CJ, Laird N, Xu X,. Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men. Hum Genet. 2006; 118: 568-77. (Pubitemid 41825129)
46. Ebeling PR,. Metabolic bone diseases: translational research-preventing fractures with denosumab. Nat Rev Rheumatol. 2009; 5: 660-1.
47. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C;, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756-65. Erratum in: N Engl J Med. 2009;361:1914.